X

Drug Profile

PNU 142731A

Latest Information Update: 06 Aug 2002

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pharmacia Corporation
Class Anti-inflammatories; Pyrimidines
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Asthma; Seasonal allergic rhinitis

Most Recent Events

06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
31 Jan 2000 Phase-I clinical trials for Seasonal allergic rhinitis in USA (Unknown route)
22 Sep 1998 Preclinical data from the 216th ACS Meeting have been added to the adverse events and pharmacokinetics sections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com